Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1999 1
2002 11
2003 9
2004 5
2005 9
2006 17
2007 23
2008 50
2009 52
2010 62
2011 77
2012 124
2013 138
2014 147
2015 160
2016 188
2017 225
2018 256
2019 292
2020 385
2021 375
2022 474
2023 491
2024 211

Text availability

Article attribute

Article type

Publication date

Search Results

3,385 results

Results by year

Filters applied: . Clear all
Page 1
Exploratory biomarker analysis in the phase III L-MOCA study of olaparib maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer.
Li H, Peng Z, Zhu J, Zhao W, Huang Y, An R, Zheng H, Qu P, Wang L, Zhou Q, Wang D, Lou G, Wang J, Wang K, Kong B, Xie X, Yin R, Low J, Rozita AM, Sen LC, Meng YC, Kiong KS, Liu J, Liang Z, Lv W, Zhu Y, Hu W, Sun W, Su J, Wang Q, Zang R, Ma D, Gao Q. Li H, et al. Among authors: wang k. BMC Med. 2024 May 16;22(1):199. doi: 10.1186/s12916-024-03409-9. BMC Med. 2024. PMID: 38755585 Free PMC article. Clinical Trial.
Senaparib as first-line maintenance therapy in advanced ovarian cancer: a randomized phase 3 trial.
Wu X, Liu J, Wang J, Wang L, Lin Z, Wang X, Zhu J, Kong B, Fei J, Tang Y, Xia B, Liang Z, Wang K, Huang Y, Zheng H, Lin A, Jiang K, Wang W, Wang X, Lou G, Pan H, Yao S, Li G, Hao M, Cai Y, Chen X, Yang Z, Chen Y, Wen H, Qu P, Xu C, Hsieh CY; FLAMES Investigators. Wu X, et al. Among authors: wang k. Nat Med. 2024 May 15. doi: 10.1038/s41591-024-03003-9. Online ahead of print. Nat Med. 2024. PMID: 38750351
Niraparib maintenance therapy using an individualised starting dose in patients with platinum-sensitive recurrent ovarian cancer (NORA): final overall survival analysis of a phase 3 randomised, placebo-controlled trial.
Wu X, Zhu J, Yin R, Yang J, Liu J, Wang J, Wu L, Liu Z, Gao Y, Wang D, Lou G, Yang H, Zhou Q, Kong B, Huang Y, Chen L, Li G, An R, Wang K, Zhang Y, Yan X, Lu X, Lu W, Hao M, Wang L, Cui H, Chen Q, Abulizi G, Huang X, Tian X, Wen H, Huang Z, Dong J, Zhang C, Hou J, Mirza MR. Wu X, et al. Among authors: wang k. EClinicalMedicine. 2024 May 7;72:102629. doi: 10.1016/j.eclinm.2024.102629. eCollection 2024 Jun. EClinicalMedicine. 2024. PMID: 38745967 Free PMC article.
3,385 results